KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBIT Margin: 2020-2025

Historic EBIT Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -3,327.57%.

  • Recursion Pharmaceuticals' EBIT Margin fell 295048.00% to -3,327.57% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,656.17%, marking a year-over-year decrease of 105147.00%. This contributed to the annual value of -814.09% for FY2024, which is 2876.00% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' EBIT Margin stood at -3,327.57%, which was down 262.97% from -916.75% recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' EBIT Margin registered a high of -377.10% during Q3 2024, and its lowest value of -4,042.41% during Q4 2024.
  • In the last 3 years, Recursion Pharmaceuticals' EBIT Margin had a median value of -908.36% in 2023 and averaged -1,320.77%.
  • Its EBIT Margin has fluctuated over the past 5 years, first spiked by 2,938,181bps in 2021, then crashed by 313,405bps in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' EBIT Margin (Quarterly) stood at -2,564.55% in 2021, then skyrocketed by 211,864bps to -445.91% in 2022, then tumbled by 46,246bps to -908.36% in 2023, then tumbled by 313,405bps to -4,042.41% in 2024, then plummeted by 295,048bps to -3,327.57% in 2025.
  • Its last three reported values are -3,327.57% in Q3 2025, -916.75% for Q2 2025, and -1,297.85% during Q1 2025.